1 Result(s)

Article

Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Improving glucose sensitivity remains an unmet medical need in treating type 2 diabetes (T2D). Dorzagliatin is a dual-acting, orally bioavailable glucokinase activator that enhances glucokinase activity in a g...

Dalong Zhu, **aoying Li, Jianhua Ma, Jiao’e Zeng, Shenglian Gan… in Nature Medicine (2022)